C3orf62 and neoplasm: Although in some cases few neoantigens are sufficient to control the tumor or reach a therapeutic effect (20, 21), these results suggest that most cancer-specific MAPs able to trigger an antitumoral T cell response are likely not originating from exonic point mutations, and that other sources of neoantigens should be explored to drive future antitumoral immunotherapies (22).